Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 9/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | C1R | P00736 | 8/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21323718 | 0.85 | ELANE (0.41) | ELANEPDE10AMEN1KMT2AC1R | |
| SCHEMBL692733 | 0.74 | ELANE (0.81) | ELANEPDE10AMEN1KMT2AC1R | |
| SCHEMBL29405904 | 0.74 | ELANE (0.81) | ELANEPDE10AMEN1KMT2AC1R | |
| SCHEMBL7519440 | 0.73 | TSHR (0.46) | PDE10AMEN1KMT2AKDM4ETSHR | |
| SCHEMBL7509246 | 0.73 | TSHR (0.46) | PDE10AMEN1KMT2AKDM4ETSHR | |
| SCHEMBL12066201 | 0.69 | PDE10A (0.61) | ELANEPDE10AMEN1KMT2AC1R | |
| SCHEMBL6082809 | 0.69 | ELANE (1.00) | ELANEPDE10AMEN1KMT2AC1R | |
| SCHEMBL5780396 | 0.69 | ELANE (0.73) | ELANEPDE10AMEN1KMT2AC1R | |
| SCHEMBL7503514 | 0.69 | TSHR (0.41) | PDE10AMEN1KMT2AKDM4ETSHR | |
| SCHEMBL692829 | 0.68 | ELANE (0.76) | ELANEPDE10AMEN1KMT2AC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2576540-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3318561-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3318561-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-06-18 | — | — | US | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2576540-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150156-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011150156-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | PDE10A, PDE2A, PDE3A | ELANE 1534/4885PDE10A 1/4885MEN1 3391/4885 |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | ELANE 3270/4885PDE10A 2086/4885MEN1 3126/4885 |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | PDE4A, PDE2A, PDE9A | ELANE 2193/4885PDE10A 6/4885MEN1 2701/4885 |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | COMT, GPR119, NLN | ELANE 3270/4885PDE10A 2086/4885MEN1 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.